Not Applicable
The present disclosure relates generally to portable oxygen concentrators and, more particularly, to a method of retrofitting a portable oxygen concentrator to interface with and enable use in a patient ventilation system.
A wide range of clinical conditions may require some form of ventilation therapy, whereby the patient's work of breathing is assisted by the flow of pressurized gas from a ventilator to the patient's airway. These conditions may include hypoxemia, various forms of respiratory insufficiency, and airway disorders. There are also non-respiratory and non-airway diseases that require ventilation therapy, such as congestive heart failure and neuromuscular diseases.
To improve the quality of life of many patients who require long-term ventilation therapy, ventilation systems have been developed which are miniaturized and portable. Some of these systems, for example, the Life2000™ system by Breathe Technologies, Inc., are so lightweight and compact that in their extended range or stand-alone configurations, they are wearable by the patient. These systems require a source of pressurized ventilation gas to operate. In the stationary or extended range configuration, the source of pressurized gas may be a stationary compressor unit, which may be kept in a patient's home. In the stand-alone configuration, which may be generally used when the patient is outside the home, the portable, wearable ventilator generally may receive its ventilation gas from a pressurized gas cylinder or a portable compressor.
Many of the above clinical conditions and other clinical conditions may also require or benefit from supplemental oxygen therapy, whereby the gas introduced to the patient's airway is augmented by the presence of additional oxygen such that the patient inspires gas having oxygen levels above atmospheric concentration (20.9% at 0% humidity). Supplemental oxygen therapy requires the patient to receive supplemental oxygen gas from an oxygen gas source, which is typically a compressed or cryogenic oxygen cylinder or an oxygen gas generator. For many years, patients who wished to be mobile relied on oxygen cylinders. However, in recent years, miniaturization and improvements in battery technology have resulted in the development of portable oxygen concentrators (POCs).
Portable oxygen concentrators typically operate by pressure swing adsorption (PSA), in which ambient air is pressurized by a compressor and passed through an adsorbent sieve bed. The sieve bed is typically formed of a zeolite which preferentially adsorbs nitrogen when at high pressure while oxygen passes through. Once the sieve bed reaches its capacity to adsorb nitrogen, the pressure can be reduced. This reduction in pressure causes the adsorbed nitrogen to be desorbed so it can be purged, leaving a regenerated sieve bed that is again ready to adsorb nitrogen. With repeated cycles of this operation, an enriched oxygen gas may be generated. Typically, portable oxygen concentrators have at least two sieve beds so that one may operate while the other is being purged of the nitrogen and vented. Typical portable oxygen concentrators today output an enriched oxygen gas with a purity of around 87-96% oxygen. Among existing oxygen concentrators today which may be considered portable (especially by an individual suffering from a respiratory condition), there are generally two types available. The first type, which is larger and heavier, is usually capable of continuous flow delivery. Models of this type typically weigh between 4-7 kg, have maximum flow rates of around 2-3 liters per minute or less, and are generally configured with wheels and a handle, often mimicking the appearance of a suitcase. The second type are lighter units more suitable for being carried or worn in a satchel, handbag, or backpack. Models of this type typically weigh less than 2.5 kg and are usually limited to pulsed delivery modes with maximum flow rates of around 1 liter per minute or less.
Portable oxygen concentrators have a substantial cost and convenience advantage over pressurized oxygen cylinders, due to the pressurized oxygen cylinders requiring ongoing refilling or replacement. Additionally, portable oxygen concentrators are considered to be significantly safer than pressurized oxygen cylinders. This safety consideration can have a substantial impact on a patient's quality of life, because many portable oxygen concentrators have been approved by the FAA for use by travelers on commercial airlines, whereas oxygen cylinders are universally banned on commercial flights. Consequently, patients with pressurized oxygen cylinders must make expensive and time-consuming preparations with an airline ahead of time, or forego airline travel entirely.
For patients with conditions where assistance with the work of breathing is not required, supplemental oxygen therapy alone, without ventilation therapy, may be sufficient. However, for many patients, combined ventilation therapy and supplemental oxygen therapy may be a more optimal treatment. In healthy patients, sufficient ventilation to perform the work of breathing may typically require minute ventilation rates of between 5 and 8 L/min while stationary, which may double during light exercise, and which may exceed 30 L/min during heavy exercise. Patients suffering from respiratory conditions may require substantially higher rates, and substantially higher instantaneous rates. This is especially true when these patients are outside the home and require portability, as at these times such patients are often also involved in light exercise.
It may thus be seen that patients who would prefer to receive this combined mode of treatment are substantially limited, due to the fact that in many cases existing portable oxygen concentrators do not output gas at pressures and/or volumes high enough to be used with a wearable, portable ventilator without the presence of an additional source of compressed gas. As such, when maximum portability is desired, these patients must either forego the substantial benefits of a portable oxygen concentrator and return to oxygen cylinders (which may output oxygen gas at the higher pressures and flow rates required for ventilation therapy), or additionally have with them a portable compressor, with the portable oxygen concentrator, the portable compressor, and the wearable ventilator interfaced together. Existing systems and methods are generally deficient in maximizing patient mobility by providing a combined supplemental oxygen/ventilation system that is lightweight and small enough to be entirely carried and/or worn by the patient.
To solve these and other problems, a portable oxygen concentrator retrofit system and method is contemplated in which an existing portable oxygen concentrator may be retrofitted to output an enriched oxygen gas at a flow rate suitable for use in a patient ventilation system without the need for an external source of compressed gas.
A method of retrofitting an existing portable oxygen concentrator for use in a patient ventilation system is contemplated, with the existing portable oxygen concentrator having at least one compressor, one or more sieve beds downstream of the compressor, one product tank downstream of the sieve beds, the product tank having an internal capacity of less than 300 ml (e.g. 50 to 100 ml for a typical portable oxygen concentrator), and a downstream gas path in fluid communication with the product tank, the downstream gas path having at least one existing pressure regulator, one existing flow valve, and perhaps one existing filter integrated therein. The method is contemplated as comprising the steps of: (1) replacing the existing product tank with one of increased capacity or supplementing the existing product tank with one or more supplemental product tanks, such that the aggregate internal capacity of any product tank(s) is large enough to accommodate a normal patient breath size (e.g. 300 ml or more or preferably 500 ml or more); (2) placing a ventilation gas path in fluid communication with the downstream gas path; and (3) configuring the downstream gas flow path such that substantially all of the gas flowing into the downstream gas path from any product tank(s) flows to the ventilation gas path without flowing through (therefore effectively bypassing) any pressure regulator(s), flow valve(s) and/or filter(s).
It is contemplated that the ventilation gas path may comprise a pressure sensor. It is additionally contemplated that the configuring step may be performed by removing any existing pressure regulator, flow valve and filter. It is further contemplated that the configuring step may be performed by placing the ventilation gas path in fluid communication with the downstream gas path upstream from any existing pressure regulator, flow valve and filter, and diverting substantially all of the gas flowing into the downstream gas path to the ventilation gas path.
It is further contemplated that the existing portable oxygen concentrator may comprise an existing external housing, and wherein following performance of the method, no portion of any existing or supplemental product tank is outside of the existing external housing.
These and other features and advantages of the various embodiments disclosed herein are better understood with respect to the following descriptions and drawings, in which:
According to various aspects of the present disclosure, retrofitted portable oxygen concentrator systems and methods of manufacturing a retrofitted portable oxygen concentrator system from an existing portable oxygen concentrator are contemplated. The retrofit process involves (1) replacing and/or supplementing the preexisting product tank of the existing portable oxygen concentrator such that the overall internal volume of the product tank(s) within the retrofitted portable oxygen concentrator meets or exceeds a volume that can accommodate a normal patient breath size (e.g. 300 ml or more or preferably 500 ml or more); and (2) bypassing the preexisting pressure regulator and/or flow valve and/or filter such that substantially all of the gas output from the product tank(s) may be output to a ventilator or otherwise used in a patient ventilation system (e.g. used for integrated ventilator functionality of the retrofitted portable oxygen concentrator system) without encountering the preexisting pressure regulator and/or flow valve and/or filter. In such a way, it may be seen that oxygen-enriched gas may be output from the retrofitted portable oxygen concentrator system at pressures sufficient to enable direct interfacing with a portable, wearable ventilator without requiring further input of pressurized gas from an additional pressurized gas source. The oxygen-enriched gas output from the retrofitted portable oxygen concentrator may also be configured in various ways to increase the volume of gas delivered to the ventilator or ventilator functionality without requiring the presence of further pressurized gas sources, such as via various entrainment systems which may increase the volume while lowering the overall oxygen concentration of the gas delivered to the ventilator proportionally, which may permit a mode of combined ventilation/oxygen supplementation therapy whereby the patient receives a moderately oxygen-enriched ventilation gas with an oxygen concentration between the highly enriched oxygen gas output by the portable oxygen concentrator and the non-enriched atmospheric gas that would be output by a compressor alone.
Turning now to
In such an exemplary portable oxygen concentrator 100, the output from the product tank 130 is flowed through a downstream gas flow path 180 where it may encounter one or more of a pressure regulator 140 or a flow valve 160, and also may encounter a filter 150, prior to being output from the portable oxygen concentrator 100. The function of the pressure regulator 140 may be to reduce the pressure of the oxygen-enriched gas contained in the product tank 130 without necessarily diluting the oxygen content of the oxygen-enriched gas. The function of the filter 150 may be to prevent passage of solid particulate matter to the patient 13 which may have been introduced into the concentrator 100 via the compressor intake 170, or other sources of solid particulate matter which may enter into the downstream gas path 180, such as broken-off particles of sieve bed material. The function of the flow valve 160 may be to alter the flow characteristics of the highly enriched gas output from the oxygen concentrator 100, such as increasing or reducing the volume flowed out via expansion or constriction of the size of a passageway, or, especially in smaller wearable/carriable embodiments of portable oxygen concentrators, via configuring the output of oxygen-enriched gas to occur in a pulsed mode whereby a bolus of a specified volume of gas is caused to emit from the flow valve 160 at specified intervals, with these volumes and/or intervals generally being adjustable by the patient 13 according to their oxygen needs. Once emitted, regardless of whether in a pulsed mode or in a continuous flow mode, the enriched oxygen gas is generally carried to the patient 13 through a patient apparatus 12, with the patient ultimately inspiring the enriched oxygen gas.
Turning now to
Turning now to
As may be appreciated, the retrofitted portable oxygen concentrator 130a, 130b is not limited to the two exemplary embodiments, but rather the retrofit process may be accomplished in a number of fashions. For example, the existing product tank 130 may be replaced with one or more supplemental product tanks 130b or left in place or relocated while also being supplemented by one or more supplemental product tanks 130b. The important consideration is that the total aggregate internal capacity of the product tanks 130, 130a, 130b to which the enriched oxygen gas is output to from the sieve beds 120 be large enough to accommodate a normal patient breath size (e.g. 300 ml or greater or more preferably 500 ml or greater), and the retrofitted portable oxygen concentrator 100a, 100b is configured such that substantially all of the gas flowing from the ultimate configuration of the product tank(s) 130, 130a, 130b flows to the ventilation gas path 180a and substantially none of the gas flows to or through any of a pressure regulator 140, a flow valve 160, and/or a filter 150. It may be seen that in some embodiments, the product tank(s) 130, 130a, 130b of the retrofitted portable oxygen concentrator 100a, 100b may be entirely contained within the existing housing provided with the original portable oxygen concentrator 100, which may be accomplished, for example, via the removal of certain portions not necessary in the final retrofitted portable oxygen concentrator 100a, 100b such as pressure regulators 140, filters 150, and flow valves 160. It may also be seen that in other embodiments, the supplemental product tank 130b which may or may not be a replacement for existing product tank 130, may be provided as an attachment to the existing portable oxygen concentrator housing or otherwise at least partially protrude outside of the existing housing.
With regard to the ventilation gas path 180a, the important consideration is that the ventilation gas path 180a be configured such that substantially all of the gas flowing from the enlarged product tank 130a or the existing product tank 130 with one or more supplemental product tanks 130b flows to the ventilation gas path 180a without flowing through any pressure regulators 140, flow valve 160 or filter 150. This may be achieved in a number of ways. In the exemplary embodiments, the pressure regulator 140, flow valve 160 and/or filter 150 may be removed entirely. In other embodiments, however, it may be seen that any one or more of these same components may instead be bypassed, for example, such that the ventilation gas path 180a may be fluidly connected to the downstream gas path 180 upstream of any pressure regulator 140, flow valve 160 and/or filter 150, with the downstream gas path 180 blocked off downstream of the point where the ventilation gas path 180a connects to it and upstream of any pressure regulator 140, flow valve 160 and/or filter 150.
It is further contemplated that a pressure sensor 190 may be arranged to measure the pressure in the product tank 130, 130a, 130b. For example, the ventilation gas path 180a may include a pressure sensor 190, or a pressure sensor 190 may be upstream of the product tank 130, 130a, 130b. The pressure sensor 190 may be operative to sense the pressure of the gas in the product tank 130, 130a, 130b or flowing through the ventilation gas path 180a, and may sense pressure directly, such as through force collection (i.e. diaphragms, pistons, bourdon tubes, or bellows) or through piezoresistive, piezoelectric, capacitive, electromagnetic, potentiometric, or optical methods, or may measure pressure through other means, such as through resonant, thermal or ionization means. The pressure sensor 190 may also be another type of sensor which may be used, alone or in combination with other components, to derive the pressure of the gas flowing through the ventilation gas path 180a via measuring something other than pressure. For example, but without limitation, the pressure sensor 190 may be another type of sensor such as a flow meter which, alone or in coordination with other sensors or components either within the retrofitted portable oxygen concentrator 100a, 100b or external thereto (such as within a portable ventilator 200 with which the sensor may communicate), may function to derive the pressure as a function of measured flow.
The above description is given by way of example, and not limitation. Given the above disclosure, one skilled in the art could devise variations that are within the scope and spirit of the invention disclosed herein. Further, the various features of the embodiments disclosed herein can be used alone, or in varying combinations with each other and are not intended to be limited to the specific combination described herein. Thus, the scope of the claims is not to be limited by the exemplary embodiments.
This application relates to and claims the benefit of U.S. Provisional Application No. 62/849,705, filed May 17, 2019 and entitled “PORTABLE OXYGEN CONCENTRATOR RETROFIT SYSTEM AND METHOD,” the entire contents of which is expressly incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
6605136 | Graham et al. | Aug 2003 | B1 |
6824590 | Dee et al. | Nov 2004 | B2 |
7066985 | Deane et al. | Jun 2006 | B2 |
7135059 | Deane et al. | Nov 2006 | B2 |
7279029 | Occhialini et al. | Oct 2007 | B2 |
7438745 | Deane et al. | Oct 2008 | B2 |
7473299 | Occhialini et al. | Jan 2009 | B2 |
7585351 | Deane et al. | Sep 2009 | B2 |
7686870 | Deane et al. | Mar 2010 | B1 |
7708802 | Deane et al. | May 2010 | B1 |
7730887 | Deane et al. | Jun 2010 | B2 |
7753996 | Deane et al. | Jul 2010 | B1 |
7780768 | Taylor et al. | Aug 2010 | B2 |
7841343 | Deane et al. | Nov 2010 | B2 |
7857894 | Taylor et al. | Dec 2010 | B2 |
7922789 | Deane et al. | Apr 2011 | B1 |
8142544 | Taylor et al. | Mar 2012 | B2 |
8366815 | Taylor et al. | Feb 2013 | B2 |
8377181 | Taylor et al. | Feb 2013 | B2 |
8440004 | Taylor et al. | May 2013 | B2 |
8568519 | Taylor et al. | Oct 2013 | B2 |
8580015 | Taylor et al. | Nov 2013 | B2 |
8702841 | Taylor et al. | Apr 2014 | B2 |
9220864 | Taylor et al. | Dec 2015 | B2 |
9283346 | Taylor et al. | Mar 2016 | B2 |
9592360 | Taylor et al. | Mar 2017 | B2 |
9907926 | Allum | Mar 2018 | B2 |
9995645 | Allum | Jun 2018 | B2 |
10004869 | Taylor et al. | Jun 2018 | B2 |
10384028 | Allum et al. | Apr 2019 | B2 |
10792453 | Allum | Oct 2020 | B2 |
10946161 | Oddo et al. | Mar 2021 | B2 |
11071841 | Edwards | Jul 2021 | B2 |
11123512 | Allum | Sep 2021 | B2 |
11278698 | Romano et al. | Mar 2022 | B2 |
11491293 | Hete et al. | Nov 2022 | B2 |
20020040714 | Yagi | Apr 2002 | A1 |
20050072423 | Deane et al. | Apr 2005 | A1 |
20050072426 | Deane et al. | Apr 2005 | A1 |
20060090759 | Howes et al. | May 2006 | A1 |
20060124128 | Deane et al. | Jun 2006 | A1 |
20060174878 | Jagger et al. | Aug 2006 | A1 |
20060292654 | Reardon | Dec 2006 | A1 |
20070039466 | Nawata | Feb 2007 | A1 |
20070125377 | Heinonen | Jun 2007 | A1 |
20080072907 | Deane et al. | Mar 2008 | A1 |
20080110338 | Taylor et al. | May 2008 | A1 |
20080202337 | Taylor et al. | Aug 2008 | A1 |
20090126736 | Taylor et al. | May 2009 | A1 |
20090131763 | Taylor et al. | May 2009 | A1 |
20140190348 | Richey, II | Jul 2014 | A1 |
20170113013 | Allum | Apr 2017 | A1 |
20170143926 | Allum et al. | May 2017 | A1 |
20170340851 | Allum et al. | Nov 2017 | A1 |
20170348501 | Taylor et al. | Dec 2017 | A1 |
20170361052 | Taylor et al. | Dec 2017 | A1 |
20180001048 | Allum | Jan 2018 | A1 |
20180200474 | Allum et al. | Jul 2018 | A1 |
20180200475 | Allum et al. | Jul 2018 | A1 |
20180364119 | Allum | Dec 2018 | A1 |
20180369531 | Taylor et al. | Dec 2018 | A1 |
20190175860 | Allum et al. | Jun 2019 | A1 |
20200155783 | Allum et al. | May 2020 | A1 |
Entry |
---|
US 10,265,491 B2, 04/2019, Allum et al. (withdrawn) |
European Search Report for EP20173839; dated Sep. 29, 2020. |
Number | Date | Country | |
---|---|---|---|
20200360644 A1 | Nov 2020 | US |
Number | Date | Country | |
---|---|---|---|
62849705 | May 2019 | US |